Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 4/20 | 0.48 |
| ▸ | BACE1 | P56817 | 4/20 | 0.48 |
| ▸ | BCHE | P06276 | 3/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | FABP6 | P51161 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1574043 | 1.00 | MEN1 (0.55) | MEN1KMT2AMAPK1GAASMN1; SMN2 | |
| SCHEMBL21777608 | 1.00 | MEN1 (0.55) | MEN1KMT2AMAPK1GAASMN1; SMN2 | |
| SCHEMBL21777609 | 1.00 | MEN1 (0.55) | MEN1KMT2AMAPK1GAASMN1; SMN2 | |
| SCHEMBL21773164 | 1.00 | MEN1 (0.55) | MEN1KMT2AMAPK1GAASMN1; SMN2 | |
| SCHEMBL21773167 | 1.00 | MEN1 (0.55) | MEN1KMT2AMAPK1GAASMN1; SMN2 | |
| SCHEMBL1574067 | 0.88 | MEN1 (0.44) | MEN1KMT2AMAPK1GAASMN1; SMN2 | |
| SCHEMBL1574069 | 0.88 | MEN1 (0.44) | MEN1KMT2AMAPK1GAASMN1; SMN2 | |
| SCHEMBL21794034 | 0.82 | CHRM1 (0.51) | MEN1KMT2AMAPK1GAASMN1; SMN2 | |
| SCHEMBL3069424 | 0.82 | CHRM1 (0.51) | MEN1KMT2AMAPK1GAASMN1; SMN2 | |
| SCHEMBL3604680 | 0.82 | CHRM1 (0.51) | MEN1KMT2AMAPK1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2020-08-25 | — | — | US | disclosed |
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | US | disclosed |
| EP-1140085-B1 | AZABICYCLOALKANES AS CCR5 MODULATORS | PHIVCO UK LTD (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-6586430-B1 | Administering azabicyclo compounds to treat human immunodeficiency virus infections and respiratory system disorders | PFIZER INC. | 2003-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | SCN1A, SCN2A, SCN2B | MEN1 1771/4885KMT2A 983/4885MAPK1 2724/4885 |
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | SCN1A, SCN2A, SCN2B | MEN1 1771/4885KMT2A 983/4885MAPK1 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.